Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Hands holding a glass lung

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

Clinical Research Standardized Reading Procedures iRECIST RECIST Research with mint mintLesion

Related Resources

Related Resources

University Hospital Ulm: Pilot study shows discriminatory power of MRI-based 3d texture analysis for bone lesions

Distinguishing between enchondroma, a benign tumor, and low-grade chondrosarcoma, which is a low-aggressivity malignancy, is a frequent challenge, as…

4 Questions – 4 Answers // Imaging in Clinical Trials

Mint Medical, Inc. Vice President of Clinical Trials, Kelie Luby Discusses Advances in Imaging Analysis in Clinical Trials and What’s Next for Mint…

Joint partnership between Mint Medical and Siemens Healthineers syngo.via

Siemens Healthineers and Mint Medical joined forces to accelerate imaging and result reporting software availability in hospitals when and where it is…